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ABSTRACT 
Formation of dextrorphan (DXT) from dextromethorphan (DXM) has been widely used to assess 
cytochrome P450 2D (CYP2D) activity. Additionally, the kinetics of CYP2D activity have been 
well characterized in the liver microsomes. However, studies in brain microsomes are limited 
due to the lower microsomal content and abundance of CYP2D in the brain relative to the liver. 
In the present study, we developed a micro-scale enzymatic incubation method, coupled with a 
sensitive UPLC-MS/MS assay for the quantitation of the rate of DXT formation from DXM in 
brain microsomes. Rat brain microsomes were incubated with different concentrations of DXM 
for various times.  The reaction was stopped, and the proteins were precipitated by the addition 
of acetonitrile, containing internal standard (d3-DXT). After centrifugation, supernatant (2 µL) 
was injected onto a UPLC, C18 column with gradient elution. Analytes were quantitated using 
triple-quadrupole MS/MS with electrospray ionization in positive ion mode. The assay, which 
was validated for accuracy and precision in the linear range of 0.25 nM to 100 nM DXT, has a 
lower limit of quantitation of 0.125 fmol on the column. Using our optimized incubation and 
quantitation methods, we were able to reduce the incubation volume (25 µL), microsomal protein 
amount (5 µg), and incubation time (20 min), compared with reported methods. The method was 
successfully applied to estimation of the Michaelis-Menten (MM) kinetic parameters of 
dextromethorphan-O-demethylase activity in the rat brain microsomes (mean ± SD, n = 4), 
which showed a maximum velocity of 2.24 ± 0.42 pmol/min/mg and a MM constant of 282 ± 62 
µM. It is concluded that by requiring far less biological material and time, our method represents 
a significant improvement over the existing techniques for investigation of CYP2D activity in rat 
brain microsomes.   
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1.  Introduction 
The dextromethorphan-O-demethylase (DOD) activity assay, where dextromethorphan 
(DXM) is biotransformed into the metabolite dextrorphan (DXT) (Fig. 1), is a commonly used 
tool to estimate cytochrome P450 (CYP) 2D6 (CYP2D6) function in humans  [1, 2]. The DOD 
assay is also used in animal studies (especially in rats) to compare human CYP2D6 substrate 
specificities with those in other species [3-7]. In rodents, this activity is more generally assigned 
to the CYP2D subfamily, given there are multiple isoforms within this subfamily with similar 
homology and substrate affinities that overlap with the human CYP2D6 isoform [8-10]. 
In both humans and rats, CYP2D is expressed in both the liver and brain [11-13]. Although 
the liver is considered the main site of drug clearance and metabolism, studies have shown that 
the expression and activity of CYP2D in the brain can alter pharmacologic responses to 
centrally-acting drug [5, 6, 12, 14-17]. Functional characterization of CYP enzymes in vitro is 
typically achieved via subcellular fractionation and collection of the small vesicles formed by the 
endoplasmic reticulum, called microsomes. Hepatic microsomes are routinely used in drug 
metabolism assays given the high abundance of CYP protein located there [2]. The principal 
limitation for functional assays of CYP enzymes in the brain is their relatively low abundance, 
which is approximately 1-4% of that in the liver with the exception of some specific brain 
regions [11, 13, 18]. Indeed, the microsomal protein content in the brain (2-4 mg per gram of 
brain tissue) [19] is much lower relative to that in the liver (30-40 mg per gram of liver tissue) 
[20]. In rodent studies, this limitation is exacerbated by the small quantity of brain tissue in these 
species. Thus, there are few studies in the literature where the characterization of DOD kinetics 
in the brain microsomes has been attempted [3, 4, 7]. 
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The reported in vitro studies of CYP2D activity in rat brain microsomes [3, 4, 7] tend to 
utilize much higher protein concentrations (50-1500 µg) and much longer incubation times (1 to 
2 hours) than what are typically used with the hepatic microsomes. These conditions are 
apparently necessary so that the reaction can produce enough metabolite to be accurately 
quantified. However, this exacerbates the issue of overall lower amounts of microsomal protein 
available from a single brain, such that pooling of several brains to generate enough material for 
these assays is necessary [3, 4, 7]. Other studies [5, 6, 10] have utilized something called the 
“total membrane fraction,” which is a pooling of both mitochondrial and microsomal 
membranes, to increase yield. However, these studies [5, 6, 10] still require long incubation 
times (2-3 hours) and high protein quantities (1.5-3 mg membrane protein/reaction). 
To circumvent the barriers in the studies of DOD activity in rodent brain tissue, we present 
here an optimized micro-scale enzymatic incubation method, coupled with a validated and 
sensitive UPLC-MS/MS assay for quantification of DOD activity in rat brain microsomes. The 
relatively high analytical sensitivity of the assay, along with the use of a pure DXM substrate 
that is devoid of DXT impurity, allowed us to measure the lower concentrations of DXT 
produced at relatively low microsomal protein amounts and short incubation periods. The 
application of the method to determination of the Michaelis-Menten (MM) kinetic parameters of 
DXM demethylation in rat brain microsomes is also demonstrated. This method will be useful 
when applied to animal studies investigating the effect of drug-drug interactions or disease 
pathologies related to the CYP2D activity in the brain. 
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2.  Materials and methods 
2.1.  Chemicals 
Three different stock sources for dextromethorphan hydrobromide salt (DXM-HBr) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA): DXM-HBr #1 (catalog #: D9684), DXM-
HBr #2 (catalog #: PHR1018), and DXM-HBr #3 (catalog #: D2531). Dextromethorphan base 
reference standard (DXM-USP) was purchased from the United States Pharmacopeial 
Convention (Rockville, MD, USA). Analytical metabolite standard solutions for DXT tartrate 
and its stable isotope d3-DXT were purchased from Cerilliant Corporation (Round Rock, TX, 
USA). UPLC/LC-MS grade solvents (acetonitrile, methanol, and water) were purchased from 
VWR (Radnor, PA, USA). All other reagents were analytical grade and were obtained from 
commercial sources. 
2.2.  Instrumentation 
The UPLC-MS/MS system consisted of a Bruker EVOQ triple quadrupole mass 
spectrometer, attached to the Bruker Advance UPLC system with an integrated column oven, 
degasser, and a CTC PAL autosampler. The system was controlled and the data acquired and 
quantified by the Bruker MSWS 8 software. The chromatographic separation was achieved using 
a Phenomenex Kinetex 1.7 µm C18 (100 A, 50 x 2.1 mm) column, connected to a Phenomenex 
C18 SecurityGuard ULTRA (2.1 mm) pre-column and maintained at 40
0
C. Samples (2 µL) were 
injected onto the column and eluted at a flow rate of 0.2 mL/min under gradient conditions 
consisting of solvent A (5 mM ammonium formate: formic acid, 100:0.05) and solvent B 
(acetonitrile: methanol: formic acid, 95:5:0.05). Gradient conditions were as follows: 0-0.5 
minutes, 10% B; 0.5-4 min, linear gradient 10-90% B; 4-7 min, 90% B; 7 min, 10% B; 7-9 min, 
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10% B. However, MS data were collected from 1 to 4 min only, and the valve was diverted to 
waste before and after that time.  
The mass spectrometer source utilized heated electrospray ionization (needle temperate 
300
0
C, flow 40 psi; cone temperature 300
0
C, flow 20 psi; nebulizer gas flow 50 psi) in positive 
ion mode at 3000 V. Metabolite and internal standard (IS) were analyzed using selected reaction 
monitoring for the parent/fragment transitions for DXT (m/z 258  156.90) and d3-DXT (m/z 
261  156.90). 
2.3.  Standard curves 
Stock solutions of DXT tartrate (equivalent to 1 mg/mL DXT base in methanol) and d3-DXT 
(100 µg/mL in methanol) were used as supplied by Cerilliant. Dextrorphan tartrate was diluted to 
a concentration of 1 µg/mL (DXT base) in acetonitrile, and then further diluted to a working 
stock solution of 200 nM in 100 mM Tris buffer. For calibration curves, blank samples 
containing 0.2 mg/mL brain microsomal protein in Tris buffer were spiked with stock solutions 
in buffer to give concentrations of 0.25, 0.5, 1, 2, 5, 10, 20, 50, and 100 nM. The internal 
standard d3-DXT was diluted to 10 nM in acetonitrile. Calibration curves were constructed by 
plotting the analyte: IS peak area ratios versus the added concentrations of DXT. 
2.4.  Sample preparation 
Calibration standards or metabolic incubation samples (25 µL) in a microcentrifuge tube 
were mixed with 75 µL of an ice-cold solution of IS (10 nM) in acetonitrile. Subsequently, tubes 
were vortex-mixed for 10 sec and centrifuged at 12,000 g-force for 5 minutes to precipitate 
proteins. The supernatant was collected into HPLC vials for analysis. 
2.5.  Method validation 
2.5.1.  Accuracy and precision 
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The inter- and intra-run accuracies and precision of the method were evaluated based on the 
quantitation of quality controls at DXT concentrations of 0.25, 5, and 100 nM (n = 5 per each 
concentration) against calibration standards, which were prepared from different stock solutions. 
The accuracy was calculated by measured concentration x 100/nominal concentration. Precision 
was calculated as a percent of the relative standard deviation (R.S.D). The acceptable range for 
both inter- and intra-run accuracies was considered 85-115% for middle and high concentrations, 
and 80-120% for the low concentration [21]. The acceptable precision values were 15% (middle 
and high concentrations) and 20% (low concentration) [21]. 
2.5.2.  Linearity 
The linearity of the calibration curves was evaluated by the coefficient of determination (r
2
) 
of the linear regression analysis of the analyte: IS peak area ratios versus spiked concentrations 
of DXT using a weight of 1/x, where x is the spiked concentration of DXT. 
2.5.3.  Overall and Matrix Recovery 
The overall and matrix recoveries of DXT and IS from the samples containing brain 
microsomes (0.2 mg/mL protein) were determined in five replicates of three concentrations from 
the calibration curve (0.25, 5, and 50 nM). The overall recovery (recovery from protein 
precipitation plus matrix effect) was estimated by comparing samples and references prepared in 
the presence and absence of microsomes, respectively. The matrix recovery was estimated by 
preparing blank samples and references in the presence and absence of matrix, respectively, 
followed by protein precipitation and addition of DXT and IS directly to the resultant 
supernatants. In both cases, the absolute peak areas of DXT or IS in the samples were compared 
with those in their respective references, and recoveries were presented as percentages of the 
references.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 9 
2.6.  DXT impurity in the DXM substrate from different sources 
The extent of DXT impurities in DXM stock solutions (1000 µM), which were prepared from 
three different DXM-HBr powders and a DXM base reference standard (DXM-USP), were 
tested by quantitating DXT concentrations using the LC-MS/MS method. The extent of impurity 
was then  calculated as the molar concentration of DXT impurity divided by the molar 
concentration of DXM, multiplied by 100.   
2.7. Preparation of microsomes from whole rat brain 
Frozen whole brains from adult (8 to 12-week old), male Sprague-Dawley rats were 
purchased from Innovative-Research (Novi, Michigan, USA). Whole brains were homogenized 
in ice-cold buffer (100 mM Tris, 0.2 mM EDTA, and 1.15% KCl; pH 7.4) at a 1:10 ratio using 
an electric motor-driven Potter-Elvehjem Teflon homogenizer. Homogenate was spun at 1,300 g 
for 5 minutes at 4
o
C. The supernatant was collected, and the pellet washed with the 
homogenizing buffer and centrifuged again at 1,300 g for 5 minutes. The supernatants were 
combined and spun at 21,000 g for 12 minutes at 4
o
C to pellet mitochondria. The supernatant 
was collected and spun at 110,000 g for 70 minutes to obtain microsomes. The supernatant was 
discarded, and the pellet was washed and centrifuged again using fresh homogenization buffer. 
The microsomal pellet was collected and re-suspended in a storage buffer (100 mM Tris, 0.2 mM 
EDTA, 1.15% KCl, 20% glycerol, 0.1 mM dithiothreitol, 22 µM butylated hydroxytoluene, and 
0.1 mM phenylmethylsulfonyl fluoride; pH 7.4) and stored at -80
o
C for later experiments. Total 
protein concentrations were estimated using the Bradford method. 
2.8.  Determination of the CYP2D-mediated O-demethylase activity 
DXM stock solutions were prepared by dissolving the DXM-HBr and DXM-USP powders in 
water and 5 mM excess HCl solutions, respectively. After an initial study to compare the DOD 
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activities using DXM-HBr #3 and DXM-USP stock solutions at a DXM concentration of 1000 
µM, all the MM experiments were conducted using DXM-USP at concentrations of 100, 200, 
500, 1000, 1500, and 2000 µM. To determine the inter-animal variability, the MM curves were 
constructed using four different brain tissues . Microsomal protein (5 µg) was preincubated at 
37
o
C for 5 minutes in 100 mM Tris-HCl buffer pH 7.4 with DXM substrate in a final volume of 
25 µL. The reaction was initiated by the addition of 1 mM NADPH. After 20 minutes of 
incubation at 37
o
C, reactions were terminated by the addition of ice-cold acetonitrile (75 µL), 
containing 10 nM IS (d3-DXT). Each reaction mixture was paired with its own control sample, 
containing all the elements of the reaction mixture with the exception of NADPH. The reactions 
in the control samples were immediately (time zero) terminated by the addition of ice-cold 
acetonitrile containing internal standard. Samples were centrifuged, and the supernatants were 
loaded into HPLC vials for LC-MS/MS analysis. The nonlinear regression analysis of the 
metabolism rate-substrate concentration data was fitted to a one-enzyme MM model to estimate 
the maximum velocity (Vmax) and MM constant (Km) using GraphPad Prism software (La Jolla, 
CA, USA). 
2.9.  Stability of DXT in brain microsomal incubations and during autosampler storage 
To confirm stability of the generated DXT in the brain microsomal incubations, DXT (5 nM) 
was added to the microsomal incubation samples, described above, in the presence of NADPH 
but without the addition of substrate. The concentration of DXT (5 nM) was selected to be close 
to the concentration generated near the Km of our reactions. The samples were incubated at 37
o
C 
and subjected to LC-MS/MS analysis at 0, 5, 10, 15, and 20 min after incubation (n = 3/each 
time point).  Additionally, the samples, after protein precipitation, were kept in the autosampler 
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(10
o
C) and re-injected 24 hours later to determine the autosampler stability of the processed 
samples. 
3.  Results and discussion 
3.1.  UPLC-MS/MS assay characteristics 
Figure 2 depicts the chromatograms of brain microsomal matrix for a blank brain microsomal 
sample, the lowest concentration of DXT (0.25 nM) in the calibration curve, and the IS (d3-
DXT). Under the chromatographic conditions described in the methods section, DXT and IS 
eluted at 2.75 min as sharp peaks with low baseline noises.  
The overall and matrix recoveries of DXT from the brain microsomal samples at low, 
middle, and high concentrations in the calibration curve are presented in Table 1, along with 
their respective internal standard (single concentration of 10 nM). Whereas the matrix recovery 
is influenced by the matrix only, the overall recovery reflects both matrix recovery and recovery 
from the protein precipitation procedure. The recovery of DXT and IS from the matrix, based on 
the absolute peak areas, ranged from 91% – 95% and 96% to 102%, respectively, indicating a 
lack of matrix effect. Similarly, the overall recoveries of DXT ( 91% – 106%) and IS (89% – 
108%) were relatively high, suggesting an almost complete recovery from the protein 
precipitation method and confirming the lack of matrix effect on the samples (Table 1). For both 
cases, the recoveries were independent of the concentration of DXT (one-way ANOVA). Most 
of the current LC-MS/MS assays that quantitate DXT have been developed for measurement of 
DXM and its metabolites in plasma [22] or blood [23] and require extraction procedures to 
remove substantial matrix effect of the plasma or blood. The lack of matrix effect in our studies, 
which uses protein precipitation, is most likely due to the fact that our micro-scale microsomal 
assay contains only 5 µg of proteins, as opposed to substantial proteins in the plasma and blood. 
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However, our protein precipitation method may not be suitable for plasma or blood samples 
because it may cause significant matrix effect.  
Calibration curves constructed in the range of 0.25-100 nM (prepared in brain microsomal 
matrix) were linear with r
2
 values of ≥ 0.99 for the inter- and intra-run experiments. The 
representative equation for the standard curves (calculated from the averages of the inter-day 
calibration curves) was 𝑦 = 0.0337 𝑥 − 0.00126, where 𝑦 and 𝑥 refer to the DXT: IS peak ratio 
and the concentration of DXT, respectively. The results of intra- and inter-day accuracy and 
precision experiments are reported in Table 2. The values fell within the limits of the FDA 
guidelines; the accuracy was within 94.1-111%, and the precision values (R.S.D.) were ≤ 14.9%. 
Based on the accuracy and precision values (Table 2), the lower limit of quantitation (LLOQ) for 
DXT was 0.25 nM, which translates to an equivalent of 0.125 fmol DXT on the column. 
Previous studies of the CYP2D-mediated DOD activity in the brain have relied on GC-MS 
[7] or HPLC with UV [4], fluorescence [5, 6], electrochemical [10], or MS/MS [3] detectors for 
quantification of DXT. These assays reported LLOQs or detection limits between 2 fmol to 2 
pmol, with the HPLC-MS/MS method [3] reporting the highest sensitivity. Others have also 
reported HPLC or LC methods coupled with tandem mass spectrometry for the DOD assay, 
mostly for microsomal samples from the liver [2, 24] or intestinal [20] tissues. However, these 
assays may not be directly transferrable to the brain microsomes because of low abundance of 
CYP450 in the brain tissue. The only reported LC-MS/MS assay for DOD activity in the brain 
[3] is based on an assay originally developed for the liver microsomes [24]. Although reporting a 
detection limit of 2 fmol, the assay [3] requires 50 µg of microsomal protein and uses bucetin as 
an IS, which shows a different retention time than DXT [24]. The use of deuterated DXT as IS in 
our assay is more advantageous compared with an IS with a different structure, which may show 
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a different response to matrix effect or inter- and intra-run changes to the sensitivity of the MS 
detector. Additionally, our LLOQ for DXT (0.125 fmol) is a considerable improvement to the 
LLOQ reported in the literature for the DOD assay. The higher sensitivity of our assay, 
compared with the other MS/MS assays [2, 3, 20, 24] may be partly due to our use of UPLC 
instead of HPLC. Additionally, our method has a simpler sample preparation (protein 
precipitation with acetonitrile) compared to those methods that use a more complicated liquid-
liquid extraction method for determination of DOD activity in the brain [5-7, 10, 20]. 
3.2.  DXT impurity in the DXM substrates from different sources 
Almost all of the studies of DOD activity use DXM hydrobromide (DXM-HBr), which is 
significantly more water soluble than DXM base. However, when we tested three commercially 
available powders of DXM-HBr, we noticed measurable concentrations of DXT impurity in the 
substrate. When quantified, the concentrations of DXT in 1000 µM stock solutions of the 
powders ranged from 4.17 to 9.72 nM, which translates to a very low impurity of 0.000417% to 
0.000972%, based on the molar concentrations of DXT and DXM (Table 3). We also purchased 
and tested an analytical reference standard of DXM base powder (DXM-USP). The DXM-USP 
was dissolved in dilute HCl solutions for solubility purposes. The concentration and extent of 
impurity of DXT in the DXM-USP were >10 fold lower than the corresponding values for the 
DXM-HBr powders (Table 3).  
The relatively low level of impurity of DXT in the substrate powders (Table 3) may be 
insignificant for DOD activity assays in the liver microsomes, which have high DOD activity. 
However, the impurity could potentially lead to significant errors when the production rate of 
DXT is relatively low, as is the case with the brain microsomes. Therefore, we tested the effects 
of DXT impurities on the formation rate of DXT in brain microsomes using 1000 µM 
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concentrations of DXM-HBr #3, which had the lowest degree of impurity among the three tested 
HBr powders (Table 3), and DXM-USP with a 10-fold lower impurity. Figures 3A and 3B 
demonstrate the chromatograms of DXT present in the DXM-HBr #3 and DXM-USP powders, 
respectively, immediately (time zero) and 20 min after the incubation of the brain microsomal 
samples with 1000 µM of the substrates. As expected from the data in Table 3, the DXT impurity 
peak in the DXM-HBr #3 sample (4.36 ± 0.22 nM, Fig. 3A) was ~ 10-fold larger (p < 0.0001, n 
= 5) than that in the DXM-USP sample (0.453 ± 0.044 nM, Fig. 3B). Additionally, for the DXM-
HBr #3 substrate, the DXT impurity peak appeared to substantially contribute to the DXT peak 
after 20 min of incubation with brain microsomes (Fig. 3A). However, the contribution of small 
impurity in the DXM-USP to the 20-min incubation sample seemed to be minimal (Fig. 3B).  
The higher impurity in the DXM-HBr #3 powder resulted in a significantly (p < 0.01, two-
tailed unpaired t-test, n = 5) higher (40%) DOD activity with this substrate as compared with the 
activity after the incubation with DXM-USP (Fig. 3C). However, when the production of the 
metabolite by brain microsomes was normalized to the background peak at time zero, the DOD 
activities for the two substrates became similar (Fig. 3D).  Therefore, for our incubation studies 
with brain microsomes, we used DXM-USP in addition to measurement of the DXT at both time 
zero and 20 min to account for the presence of any impurities.  
3.3. Optimization of DOD incubation conditions  
 Figures 4A and 4B depict the brain microsomal activity of DOD as a function of time and 
microsomal protein concentrations, respectively. As demonstrated in Fig. 4A, the amount of 
metabolite formed was linear up to 40 min of incubation time in the presence of 0.2 mg/mL 
protein and 200 µM DXM. Additionally, the formation rate was linear across the tested protein 
concentrations (0.1, 0.2, 0.3, and 0.4 mg/mL) after 20 min incubation of the samples with 200 
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µM DXM (Fig. 4B). From these experiments, we determined that the optimum incubation 
conditions for our kinetic experiments were 0.2 mg/mL brain microsomal protein (5 µg protein 
for an incubation volume of 25 µL) and 20 min of incubation time. Compared with our 
incubation method, which uses 5 µg microsomal protein, previous studies estimating DOD 
activity in rat brain microsomes have used much higher brain microsomal proteins of 50 µg [3], 
250 µg [4], or 1500 µg [7]. This decrease in protein amount per reaction allows for the use of 
single rat brain microsomal preparation as opposed to the pooling of multiple brains to yield 
enough microsomal material for MM studies of multiple enzymes. Additionally, a reaction time 
of 20 minutes was sufficient to produce enough metabolite for the analysis, compared to the 1-2 
hours’ time typically needed [3, 4, 7].  
Figure 4C shows the stability of the metabolite under the optimized reaction conditions as a 
function of incubation time. As demonstrated (Fig. 4C), there were no  significant changes in the 
DXT concentrations with time, which indicates that the metabolite is stable for up to 20 minutes 
of incubation with NADPH and 5 µg of brain microsomal protein. Additionally, the re-injection 
of the same samples stored for 24 hours in the autosampler (10
o
C) did not reveal any significant 
changes in the concentrations of DXT (Figure 4C) or the absolute peak values of the DXT and IS 
(data not shown) as a result of autosampler storage.  
3.4. Estimation of DOD kinetics in rat brain microsomes 
The kinetics of DOD activity in brain microsomes collected from four different animals are 
shown in Figure 4D. We observed an expected MM curve that plateaued between substrate 
concentrations of 1000 and 2000 µM. The estimated MM kinetic parameters (mean ± SD, n = 4 
animals) were a Vmax of 2.24 ± 0.42 pmol/min/mg and a Km of 282 ± 62 µM. Only two other 
studies, Jolivalt et al. [4] and Voirol et al. [7], have reported DOD kinetics in rat brain 
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microsomes. These studies used far higher protein amounts (250 and 1500 µg) and much longer 
incubation times (120 and 90 minutes), compared with our study (5 µg protein and 20 min 
incubation time). Whereas Jolivalt et al. [4] reported Vmax and Km values of 1.40 pmol/min/mg 
and 400 µM, respectively, a Vmax of 0.65 pmol/min/mg and a Km of 120 µM were reported by 
Voirol et al. [7]. Our estimated Km value (282 µM) lies in between the values reported by these 
two studies (120 and 400 µM). However, the Vmax values reported in these studies are somewhat 
lower than our observations (2.24 pmol/min/mg). In addition to these two studies, a study by 
Asai et al. [3] measured the DOD activity in the microsomes from the brain cerebellum, cortex, 
and hippocampus only at a single substrate concentration of 50 µM. In their study, the highest 
DOD activity was observed in the cerebellum microsomes, which was 0.03 pmol/min/mg. 
However, the DOD activity in the cortical and hippocampal microsomes was half of that in the 
cerebellum. This activity is far lower than what we would expect from our whole brain 
microsomal samples (~0.5 pmol/min/mg at 100 µM dextromethorphan, Fig. 4D). The lower 
DOD activities or Vmax reported in the literature for brain microsomes may be due to a variety of 
factors. First, all three studies [3, 4, 7] used an NADPH-regenerating system, which contained 
MgCl2 that can reportedly [7] inhibit CYP450 metabolism. In our preliminary studies, we also 
observed inhibition of DOD activity when using MgCl2 in our reaction buffer (data not shown). 
Additionally, these studies used longer incubation times of 60 min [3], 90 min [7], or 120 min 
[4]. Thus, the longer incubation times may be responsible for the lower metabolic capacity. This 
could be due to the inherent instability that has been reported for CYP450 in brain samples [10, 
13].  
In studies described here, we followed the rate of formation of DXT as opposed to the rate of 
decline in the concentrations of the substrate. This is because MM studies are normally carried 
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out at substrate concentrations that are expected to remain almost constant during the incubation 
period. Indeed, the concentrations of DXT formed during our 20-min microsomal incubation 
time from substrate concentrations of 100 – 2000 µM were on average equal to 2.32 – 8.39 nM, 
which are equal to 2.32% and 0.420% of the initial substrate concentrations, respectively. 
Therefore, the concentrations of the substrate remains virtually constant during the incubation 
period.      
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4. Conclusions 
In this communication, we have described a micro-scale incubation method and a sensitive 
and validated LC-MS/MS assay for the estimation of DEX demethylation activity in the rat brain 
microsomes. Collectively, these methods allowed us to substantially reduce the incubation 
volume, microsomal protein amount, and the length of incubation. The method was successfully 
applied to the estimation of CYP2D MM kinetics of the DOD activity in the brain microsomes. 
By requiring far less biological material and time, our method represents a significant 
improvement over the existing techniques for investigating CYP2D activity in rat brain 
microsomes. 
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Table 1 
 
Overall and matrix recoveries (mean ± SD) of dextrorphan and internal standard (IS) from the 
brain microsomal samples at low (0.25 nM), medium (5 nM), and high (50 nM) concentrations 
of DXT in the calibration curves (n = 5). The IS concentration was the same (10 nM) in all the 
samples. 
Concentration 
(nM) 
 
 
Overall Recovery (%) 
 
 
Matrix Recovery (%) 
 
 
Dextrorphan 
 
IS Dextrorphan IS 
 
0.25 
 
106 ± 18 
 
108 ± 8 
 
91.0 ± 25.5 
 
95.9 ± 3.76 
 
5 
 
94.1 ± 11.5 
 
96.2 ± 11.5 
 
94.6 ± 8.24 
 
96.2 ± 5.94 
 
50 
 
 
91.0 ± 16.1 
 
 
89.4 ± 15.3 
 
 
95.3 ± 4.83 
 
 
102 ± 4.64 
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Table 2 
     
Intra- and inter-run accuracy and precision values of the lowest (0.25 nM), 
middle (5 nM), and highest (100 nM) concentrations of dextrorphan in 
calibration curves for brain microsomes (n = 5). 
Concentration (nM) 
Intra-run 
 
Inter-run 
Accuracy R.S.D. 
(%) 
 Accuracy R.S.D. 
(%) 
0.25 102 14.9  111 14.5 
5 98.2  6.5  94.1  7.8 
100 100  9.4  101  1.6 
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Table 3 
Extent of dextrorphan (DXT) impurity (mean ± SD) in 4 different 
commercially-available powders of dextromethorphan (n = 5). 
DXM Stock  
(1000 µM) 
DXT impurity 
Conc. (nM) % 
DXM-HBr #1 9.72 ± 0.68 0.000972 ± 0.000068 
DXM-HBr #2 9.42 ± 0.23  0.000942 ± 0.000023 
DXM-HBr #3 4.17 ± 0.11  0.000417 ± 0.000011 
DXM-USP 0.401 ± 0.044  0.0000401 ± 0.0000044 
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Figure legends 
Figure 1. Schematic of the dextromethorphan-O-demethylase (DOD) reaction by CYP2D 
enzyme, 
where dextromethorphan (DXM) is converted to dextrorphan (DXT). 
Figure 2. Representative chromatograms of a blank brain microsomal sample (A), the lowest 
dextrorphan concentration (0.25 nM) in the calibration curve (B), and the internal standard (C). 
Figure 3. Effects of DXT impurity in the substrate on the DOD assay. (A) and (B):  
Representative chromatograms of dextrorphan in the brain microsomes immediately and 20 min 
following microsomal incubation with 100 µM DXM-HBr #3 (A) or DXM-USP (B); (C) and 
(D): The estimated rates of metabolite (DXT) formation after 20 min of brain microsomal 
incubation at 37
o
C without (C) or with (D) correction for the impurity.  ** denotes p < 0.01, 
based on unpaired, two-tailed t test.    
Figure 4. DOD assay characteristics (A-C) and Michaelis-Menten (MM) kinetics (D) in rat brain 
microsomal incubations. For time linearity (A), rat brain microsomes (n = 4) were incubated at 
0.2 mg/mL protein with 200 µM DXM. For protein linearity (B), rat brain microsomes (n = 4) 
were incubated at varying protein concentrations with 200 µM DXM for 20 minutes. For 
metabolite stability (C), dextrorphan (5 nM) was incubated (37
o
C) in brain microsomes (0.2 
mg/mL) in the presence of NADPH (1 mM), and samples (n = 3) were analyzed immediately 
(First Injection) and after 24 hours of storage (10
o
C) in the autosampler (Second Injection). For 
MM kinetics (D), incubations were carried out at 37
o
C at 0.2 mg/mL protein in a final volume of 
25 µL with 1 mM NADPH for 20 minutes (n = 4 different brains). Symbols and bars represent 
mean and SD of experimental data, respectively, and the lines are based on linear regression 
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analysis (A, B, and C) or a one-enzyme, Michaelis-Menten fit to the data (D). The slopes of the 
linear regression lines in C were not significantly different from zero. 
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